IL -17 inhibitors have established a high standard for efficacy in moderate to severe psoriasis, placing pressure on current therapies that are less efficacious and a great number of investigational therapies that are still in the pipeline. While dermatologists are becoming more comfortable prescribing an IL -17 inhibitor before TNF inhibitors, Humira, a TNF inhibitor, remains the most prescribed therapy in this highly competitive market. However, opportunity exists for emerging therapies to differentiate themselves by addressing important unmet needs that are identified in this analysis.
What are the treatment drivers and goals for moderate to severe psoriasis?
What attributes are key influencers, which have limited impact, and which are hidden opportunities?
How do current therapies perform on key treatment drivers and goals for moderate to severe psoriasis?
What are the prevailing areas of unmet need and opportunity in moderate to severe psoriasis?
What trade-offs across different clinical attributes and price are acceptable to and European dermatologists for a hypothetical new moderate to severe psoriasis drug?
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 and 30 European dermatologists fielded in February and March 2017
Key companies: AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Merck, Novartis
Key drugs: Cosentyx, Enbrel, Humira, Otezla, Remicade, Stelara, Taltz